1.87 USD
-0.2 (-9.66%)
1.88 USD
+0.01 (+0.53%)
CERS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. CERS has a bad profitability rating. Also its financial health evaluation is rather negative. CERS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CERS had negative earnings in the past year.
CERS had a positive operating cash flow in the past year.
In the past 5 years CERS always reported negative net income.
In the past 5 years CERS reported 4 times negative operating cash flow.
1.2 Ratios
CERS has a better Return On Assets (-7.42%) than 65.24% of its industry peers.
With a Return On Equity value of -25.97%, CERS perfoms like the industry average, outperforming 59.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.42% | ||
| ROE | -25.97% | ||
| ROIC | N/A |
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of CERS (60.50%) is better than 60.96% of its industry peers.
CERS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
2. Health
2.1 Basic Checks
CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CERS has more shares outstanding
CERS has more shares outstanding than it did 5 years ago.
CERS has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -4.12, we must say that CERS is in the distress zone and has some risk of bankruptcy.
CERS's Altman-Z score of -4.12 is on the low side compared to the rest of the industry. CERS is outperformed by 67.91% of its industry peers.
CERS has a debt to FCF ratio of 505.38. This is a negative value and a sign of low solvency as CERS would need 505.38 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 505.38, CERS is doing good in the industry, outperforming 66.84% of the companies in the same industry.
CERS has a Debt/Equity ratio of 0.79. This is a neutral value indicating CERS is somewhat dependend on debt financing.
CERS has a Debt to Equity ratio of 0.79. This is in the lower half of the industry: CERS underperforms 70.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 505.38 | ||
| Altman-Z | -4.12 |
ROIC/WACCN/A
WACC8.81%
2.3 Liquidity
CERS has a Current Ratio of 1.89. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.89, CERS is doing worse than 65.24% of the companies in the same industry.
A Quick Ratio of 1.29 indicates that CERS should not have too much problems paying its short term obligations.
The Quick ratio of CERS (1.29) is worse than 65.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.27%, which is quite impressive.
Looking at the last year, CERS shows a quite strong growth in Revenue. The Revenue has grown by 14.18% in the last year.
CERS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.50% yearly.
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)14.18%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%14.52%
3.2 Future
CERS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.91% yearly.
The Revenue is expected to grow by 14.35% on average over the next years. This is quite good.
EPS Next Y25.82%
EPS Next 2Y27.64%
EPS Next 3Y27.91%
EPS Next 5YN/A
Revenue Next Year24.59%
Revenue Next 2Y16.8%
Revenue Next 3Y14.35%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
CERS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, CERS is valued a bit cheaper than 66.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2138.14 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CERS's earnings are expected to grow with 27.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.64%
EPS Next 3Y27.91%
5. Dividend
5.1 Amount
No dividends for CERS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.87
-0.2 (-9.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners70.5%
Inst Owner Change-2.81%
Ins Owners2.94%
Ins Owner Change-0.24%
Market Cap359.21M
Revenue(TTM)225.97M
Net Income(TTM)-15.96M
Analysts80
Price Target4.76 (154.55%)
Short Float %3.12%
Short Ratio4.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)46.52%
Min EPS beat(2)-6.95%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)28.92%
Min EPS beat(4)-6.95%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)28.86%
EPS beat(12)7
Avg EPS beat(12)15.59%
EPS beat(16)11
Avg EPS beat(16)17.8%
Revenue beat(2)0
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-5.44%
Max Revenue beat(2)-5.03%
Revenue beat(4)1
Avg Revenue beat(4)-6.17%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-5.95%
Revenue beat(12)2
Avg Revenue beat(12)-6.05%
Revenue beat(16)6
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)62.5%
EPS NQ rev (3m)62.5%
EPS NY rev (1m)31.91%
EPS NY rev (3m)29.41%
Revenue NQ rev (1m)2.62%
Revenue NQ rev (3m)-0.79%
Revenue NY rev (1m)5.25%
Revenue NY rev (3m)-3.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.59 | ||
| P/FCF | 2138.14 | ||
| P/OCF | 100.73 | ||
| P/B | 5.84 | ||
| P/tB | 5.97 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)0
FCFY0.05%
OCF(TTM)0.02
OCFY0.99%
SpS1.18
BVpS0.32
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.42% | ||
| ROE | -25.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.5% | ||
| FCFM | 0.07% |
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score5
Asset Turnover1.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 505.38 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 248.94% | ||
| Cap/Sales | 1.5% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.89 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | -4.12 |
F-Score5
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y25.82%
EPS Next 2Y27.64%
EPS Next 3Y27.91%
EPS Next 5YN/A
Revenue 1Y (TTM)14.18%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%14.52%
Revenue Next Year24.59%
Revenue Next 2Y16.8%
Revenue Next 3Y14.35%
Revenue Next 5YN/A
EBIT growth 1Y19.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year176.36%
EBIT Next 3Y54.48%
EBIT Next 5YN/A
FCF growth 1Y100.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y111.99%
OCF growth 3YN/A
OCF growth 5YN/A
CERUS CORP / CERS FAQ
Can you provide the ChartMill fundamental rating for CERUS CORP?
ChartMill assigns a fundamental rating of 3 / 10 to CERS.
What is the valuation status for CERS stock?
ChartMill assigns a valuation rating of 2 / 10 to CERUS CORP (CERS). This can be considered as Overvalued.
How profitable is CERUS CORP (CERS) stock?
CERUS CORP (CERS) has a profitability rating of 2 / 10.
What is the earnings growth outlook for CERUS CORP?
The Earnings per Share (EPS) of CERUS CORP (CERS) is expected to grow by 25.82% in the next year.